Synthesis and evaluation of cyclic secondary amine substituted phenyl and benzyl nitrofuranyl amides as novel antituberculosis agents

Journal of Medicinal Chemistry

Volumn 48, Issue 26, 2005, Pages 8261-8269

  Tangallapally, Rajendra P ^a   Yendapally, Raghunandan ^a   Lee, Robin E ^a   Lenaerts, Anne J M ^b   Lee, Richard E ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 NITROFURAN 2 CARBOXYLIC ACID 3 (4 BENZYLPIPERAZIN 1 YL)BENZYLAMIDE; 5 NITROFURAN 2 CARBOXYLIC ACID 3,4 DIMETHOXYBENZYLAMIDE; 5 NITROFURAN 2 CARBOXYLIC ACID 4 (4 METHYLPIPERAZIN 1 YL)BENZYLAMIDE; 5 NITROFURAN 2 CARBOXYLIC ACID 4 [4 (CYCLOPROPYLMETHYL)PIPERAZIN 1 YL]BENZYLAMIDE; 5 NITROFURAN 2 CARBOXYLIC ACID 4 THIOMORPHOLIN 4 YL BENZYLAMIDE; BENZYLNITROFURANYL AMIDE DERIVATIVE; ISONIAZID; PHENYLNITROFURANYL AMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTITUBERCULAR AGENTS; BENZAMIDES; BIOLOGICAL AVAILABILITY; DRUG EVALUATION, PRECLINICAL; MICE; MYCOBACTERIUM TUBERCULOSIS; NITROFURANS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS, PULMONARY;

EID: 29744457268     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050765n     Document Type: Article

References (24)

1. Dye, C.; Scheele, S.; Dolin, P.; et al. Global burden of tuberculosis-Estimated incidence, prevalence, and mortality by country. J. Am. Med. Assoc. 282 1999, 7, 677-686.
2. World Health Organization Global Tuberculosis Programme 2005. WHO Report on the Tuberculosis Epidemic; WHO: Geneva, 2005
3. de Jong, B. C.; Israelski, D. M.; Corbett, E. L.; Small, P. M. TB and AIDS. Clinical management of tuberculosis in the context of HIV infection. Annu. Rev. Med. 2004, 55, 283-301.
4. Tangallapally, R. P.; Lee R. E.; Yendapally, R.; Hevener, K.; Jones, V. C.; Lenaerts, A. J. M.; McNeil, M. R.; Wang, Y.; Franzblau, S.; Lee, R. E. Synthesis and evaluation of nitrofuranyl amides as novel inhibitors of UDP-Gal mutase and new antituberculosis agents. J. Med. Chem. 2004, 47, 5276-5283.
5. Barry, C. E.; Boshoff, H. I. M.; Dowd, C. S. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des. 2004, 10, 3239-3262.
6. Brighty, K. E.; Gootz, T. D. Chemistry and mechanism of action of the quinolone antibacterials. In The Quinolones, 3rd ed.; Andriole, V. T., Ed.; Academic Press Inc.: San Diego, CA, 1998; pp 34-98.
7. Sensi, P.; Maggi, N.; Furesz, S.; Maffii, G. Chemical modifications and biological properties of rifamycins. Antimicrobial Agents Chemother. 1966, 6, 699-714.
8. Lauteslager, X. Y.; Van Stokkum, I. H. M.; Van Ramesdonk et al. Conformational dynamics of charge-transfer states in donor-bridge-acceptor systems. Eur. J. Org. Chem. 2001, 16, 3105-3118.
9. Brown, G. R.; Foubister, A. J.; Ratcliffe, P. D. High Yields of meta-Substituted Amination Products in the SNAr Substitution of Benzenes. Tetrahedron Lett. 1999, 40 (6), 1219-1222.
10. Valenta, V.; Protiva, M. Potential neuroleptics of the orthopramide series; synthesis of N-substituted 5-(aminosulfonyl)-2-methoxybenzamides. Collect. Czech. Chem. Commun. 1987, 52 (8), 2095-2106.
11. Takahashi, H.; Chida, Y.; Yoshii, T.; Suzuki, T.; Yanaura, S. Asymmetric α-substituted phenethylamines. VI. Synthesis and analgesic activity of optically pure (R)- and (S)-N-alkyl-1-cyclohexyl-2-phenylethylamines. Chem. Pharm. Bull. 1986, 34 (5), 2071-2077.
12. Gadwood, R. C.; Shinabarger, D. A. Progressin the oxazolidinone antibacterials. Annu. Rep. Med. Chem. 2000, 35, 135-144.
13. Hart, D. J.; Li, J.; Wu, W.; Kozikowski, A. P. Applications of organosulfur chemistry to organic synthesis: Total synthesis of (+)-himbeline and (+)-himbacine. J. Org. Chem. 1997, 62, 2 (15), 5023-5033.
14. Dess, D. B.; Martin, J. C. Readily accessible 12-I-5 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones. J. Org. Chem. 1983, 48, 8 (22), 4155-4156.
15. (b) Dess, D. B.; Martin, J. C. A useful 12-I-5 triacetoxyperiodinane (the Dess-Martin periodinane) for the selective oxidation of primary or secondary alcohols and a variety of related 12-I-5 species. J. Am. Chem. Soc. 1991, 113, 3 (19), 7277-7287.
16. For improved procedures for the preparation of DMP, see: (c) Ireland, R. E.; L. An improved procedure for the preparation of the Dess-Martin periodinane J. Org. Chem. 1993, 5, 8 (10), 2899.
17. (d) Meyer, S. D.; Schreiber, L. Acceleration of the Dess-Martin oxidation by water. J. Org. Chem. 1994, 59 (24), 7549-7552.
18. John, M. D.; Lori, D. H.; Carl, L. H.; Marland, P. H.; Thomas, F. M.; Joseph, P. S.; Marjorie, S. New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. J. Med. Chem. 1986, 29 (3), 394-404.
19. Tokuyama, R.; Takahashi, Y.; Tomita, Y.; Tsubouchi, M.; Yoshida, T.; Iwasaki, N.; Kado, N.; Okezaki, E.; Nagata, O. Structure-activity relationship (SAR) studies on oxazolidinone antibacterial agents 2. Relationship between lipophilicity and antibacterial activity in 5-thiocarbonyl oxazolidinones. Chem. Pharm. Bull. 2001, 49 (4), 353-360.
20. Lee, R. E.; Protopopova, M.; Crooks, E.; Slayden, R. A.; Terrot, M.; Barry, C. E., III Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem. 2003, 5, 172-187.
21. Gruppo, V.; Johnson, C. M.; Marietta, K. S.; Scherman, H.; Zink, E. E.; Crick, D. C.; Adams, L. B.; Orme, I. M.; Lenaerts, A. J. New strategies for the rapid screening of experimental compounds against Mycobacterium tuberculosis in the preclinical stage. Antimicrob. Agents Chemother. Submitted.
22. Lenaerts, A. J.; Gruppo, V. J.; Brooks, V.; Orme, I. M. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob. Agents Chemother. 2003, 47 (2), 783-785.
23. Kelly, B. P.; Furney, S. K.; Jessen, M. T.; Orme, I. M. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1996, 40, 12, 2809-2812.
24. Orme, I. Search for new drugs for treatment of tuberculosis. Tuberculosis drug screening program. Antimicrob. Agents Chemother. 2001, 45, 1943-1946.